TY - JOUR
T1 - Pharmacogenomic associations of adverse drug reactions in asthma
T2 - systematic review and research prioritisation
AU - King, Charlotte
AU - McKenna, Amanda
AU - Farzan, Niloufar
AU - Vijverberg, Susanne J.
AU - van der Schee, Marc P.
AU - Maitland-van der Zee, Anke H.
AU - Arianto, Lambang
AU - Bisgaard, Hans
AU - BØnnelykke, Klaus
AU - Berce, Vojko
AU - Potočnik, Uroš
AU - Repnik, Katja
AU - Carleton, Bruce
AU - Daley, Denise
AU - Chew, Fook Tim
AU - Chiang, Wen Chin
AU - Sio, Yang Yie
AU - Cloutier, Michelle M.
AU - Den Dekker, Herman T.
AU - Duijts, Liesbeth
AU - de Jongste, Johan C.
AU - Dijk, F. Nicole
AU - Koppelman, Gerard H.
AU - Flores, Carlos
AU - Hernandez-Pacheco, Natalia
AU - Pino-Yanes, Maria
AU - Mukhopadhyay, Somnath
AU - Basu, Kaninika
AU - Bignell, Lauren
AU - Tantisira, Kelan G.
AU - Turner, Steve
AU - Verhamme, Katia M.
AU - Francis, Ben
AU - Pirmohamed, Munir
AU - Sinha, Ian
AU - Hawcutt, Daniel B.
N1 - We would like to thank the NIHR Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC) for funding Amanda McKenna’s internship, and Charlotte Kings MPhil, and the members of the PiCA consortia for their help in completing the survey. U. Potočnik, K. Repnik and V. Berce were supported by SysPharmPedia grant, co-financed by Ministry of Education, Science and Sport of the Republic of Slovenia
Author information
These authors contributed equally: Charlotte King, Amanda McKenna
These authors jointly supervised this work: Ian Sinha, Daniel B. Hawcutt
PY - 2020/10
Y1 - 2020/10
N2 - A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
AB - A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.
KW - CHILDREN
KW - EXACERBATIONS
KW - RISK
KW - POLYMORPHISM
KW - BURDEN
UR - http://www.scopus.com/inward/record.url?scp=85078235110&partnerID=8YFLogxK
U2 - 10.1038/s41397-019-0140-y
DO - 10.1038/s41397-019-0140-y
M3 - Review article
C2 - 31949291
AN - SCOPUS:85078235110
SN - 1470-269X
VL - 20
SP - 621
EP - 628
JO - Pharmacogenomics Journal
JF - Pharmacogenomics Journal
ER -